Melatonin Therapy for Improving ICSI Outcomes in Women With Diminished Ovarian Reserve

Condition(s) studied

Investigational drug(s) / intervention(s)

Melatonin capsule: Participants receive 3mg of Melatonin Capsules Dosage \& Frequency: Once at night Duration: The treatment continues for 28 days

Placebo: Participants receive identical-appearing placebo capsule Dosage \& Frequency: Once at night Duration: The treatment continues for 28 days

Study summary

Diminished ovarian reserve (DOR) is a major challenge in female fertility, often leading to poor oocyte quality and low pregnancy rates during assisted reproduction. Melatonin is a potent antioxidant that may protect developing eggs from oxidative stress. This randomized clinical trial aims to evaluate whether a 4-week course of oral melatonin therapy before egg retrieval can improve the quality of oocytes and embryos, and ultimately increase pregnancy rates for women with DOR undergoing Intracytoplasmic Sperm Injection (ICSI). The study compares melatonin therapy against a placebo to assess its impact on follicular fluid health and clinical pregnancy success.

Eligibility

Primary outcome measure(s)

• The Success Rate of Treatment Regimens in Achieving Clinical Pregnancy — 2-3 Months
  The proportion of patients who achieved a clinical pregnancy (confirmed by ultrasound visualization of a gestational sac with fetal heart activity) following frozen blastocyst transfer, reflecting the effectiveness of the administered melatonin therapy.

Trial sites (1)

More Benha University trials in Egypt